MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast Cancer

MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast Cancer

Although MASTL (microtubule-associated serine/threonine kinase-like) is an attractive target for anticancer treatment, MASTL inhibitors with antitumor activity have not yet been reported. In this study, we have presented a novel MASTL inhibitor, MKI-1, identified through in silico screening and in v...

Full description

Bibliographic Details
Main Authors: Ah-Young Kim, Yi Na Yoon, Jiyeon Leem, Jee-Young Lee, Kwan-Young Jung, Minsung Kang, Jiyeon Ahn, Sang-Gu Hwang, Jeong Su Oh, Jae-Sung Kim
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
MASTL
PP2A
antitumor
breast cancer
radiosensitizer
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.571601/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.571601/full

Similar Items